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Abstract: The Psammomys obesus lives in natural desert habitat on low energy (LE) diet, however when maintained in 
laboratory conditions with high energy (HE) diet it exhibits pathological metabolic changes resembling those of type 2 diabetes. 
We have evaluated and correlated the histopathology, metabolic and functional renal alterations occurring in the diabetic 
Psammomys. Renal function determined by measuring glomerular filtration rate (GFR), protein excretion, protein/creatinine 
ratio and morpho-immunocytochemical evaluations were performed on HE diet diabetic animals and compared to LE diet 
control animals. The diabetic animals present a 54% increase in GFR after one month of hyperglycemic condition and a decrease of 
47% from baseline values after 4 months. Protein excretion in diabetic animals was 5 folds increased after 4 months. Light microscopy 
showed an increase in glomeruli size in the diabetic Psammomys, and electron microscopy and immunocytochemical quantitative 
evaluations revealed accumulation of basement membrane material as well as frequent splitting of the glomerular basement 
membrane. In addition, glycogen-filled Armanni-Ebstein clear cells were found in the distal tubules including the thick ascending 
limbs of the diabetic animals. These renal complications in the Psammomys, including changes in GFR with massive proteinuria 
sustained by physiological and histopathological changes, are very similar to the diabetic nephropathy in human. The Psamommys 
obesus represents therefore a reliable animal model of diabetic nephropathy. 
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physiological stages, including an early stage of glomerular 
hyperfiltration, followed by the silent phase in which 
glomerular filtration rate (GFR) returns to normal [3]. 
The last stage is characterized by sequential development 
of microalbuminuria, and progressive decline in GFR 
leading to renal failure [4]. Different animal models of rats 
and mice are used to study the diabetic nephropathy [5-
9]. These models have focused on the earlier harbingers of 
nephropathy, including the development of albuminuria and 
histological changes, but not on renal insufficiency as an end 
point [10]. In a previous study on long-term streptozotocin-
induced diabetes in rats, we showed a continued increase 
Introduction
Diabetic nephropathy is a clinical syndrome characterized 
by persistent microalbuminuria in concomitance with in-
sulin- or non-insulin-dependent diabetes [1, 2]. The human 
nephropathy proceeds through several distinct patho-Psammomys: a model for diabetes nephropathy
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in GFR up to 40 weeks and then a decline, but never below 
the normal levels [8]. Our findings question reliability of the 
streptozotocin diabetic model for the investigation of human 
nephropathy, as renal failure is not achieved. This stresses 
out the need for new animal models that mimic the human 
diabetic nephropathy. 
Psammomys obesus (often referred to as the “sand rat”) 
is prone to develop obesity, hyperglycemia and hyperin-
suli  nemia when fed a high energy (HE) diet [11]. The 
Psammomys is genetically predisposed to non-insulin-
de  pendent diabetes mellitus, whereas environmental and 
nutritional factors contribute to the expression of diabetes. 
The progression of the nutritionally induced diabetes in 
Psammomys resembles in many respects that occurring in 
human, with hyperglycemic-hyperinsulinemic disorders 
[12]. The prolonged state of hyperglycemia leads to several 
complications in the Psammomys model, such as cataracts 
[13], neuropathy [13], nephropathy and renal failure [14].
A previous study from our laboratory [14] showed that after 
feeding a HE diet, the Psammomys becomes hyperglycemic 
and hyperinsulinemic and develops diabetes. According to 
their renal function, we herein show that animals in an early 
diabetes state have a high GFR, whereas in advanced stages 
the animals display low GFR, similar to diabetic chronic renal 
disease. The diabetic Psammomys were also characterized 
by an increase in urinary protein excretion, and a decrease 
in the Na-K-ATPase activity in the kidney medulla. As the 
Psammomys developed signs of diabetic nephropathy only at 
4 weeks, we suggested that they may offer a more appropriate 
animal model for human diabetic nephropathy. In order 
to verify our hypothesis, we evaluated whether diabetic 
Psamommys will develop nephropathy and renal failure after 
relatively longer periods of time (16 weeks). 
Diabetic albuminuria in human is associated with the 
development of characteristic renal-histopathologic features 
which include: glomeruli, tubules, interstitium, and the blood 
vessels. There may be tubular changes secondary to alterations 
in the perm-selectivity of the glomerulus, including extensive 
glycogen deposition in the tubular cells, i.e., the Armanni-
Ebstein lesions [15]. In diabetic patients, the presence of 
glycogen in nephron was first demonstrated by Armanni and 
Ebstein in 1877 [15] and named Armanni-Ebstein lesion (AE). 
In experimental diabetes, AE has been established in the thick 
ascending limb of Henle's loop (TAL) and distal tubules [16]. 
The introduction of insulin led to a considerably reduction 
of these lesion in human [15], although some insulin-treated 
patients may still present it [17]. 
In the present study, Psammomys in uncontrolled glycemic 
state developed type 2 diabetes and, similar to the findings 
in human, their GFR changed from early to advanced stages 
accompanied by increasing proteinuria, tubular damage and 
renal failure. 
A certain correlation between the physiological and the 
structural changes was demonstrated.
Materials and Methods
Animals and tissue sampling
All animal experiments were approved by the Institutional 
Animal Welfare Committee. 
Thirty-six male Psammomys obesus, aged 6 weeks and 
weighing 170 g, of the Hebrew University strain, were used. 
Each animal was housed in an individual cage with water and 
food intake ad libitum. At the beginning of the experiments, 
the animals were anaesthetized with ketamine/xylazine 
(85%/15%) at 0.1 ml/100 g body weight, and blood was 
drawn for baseline determinations of glucose, insulin and 
creatinine levels. For kidney function, the animals were kept 
in metabolic cages. Urine creatinine and protein excretion 
were determined in four hr urine collection. The animals were 
divided randomly into 2 groups: 1) control group, consisting 
of 12 normoglycemic animals fed a low energy laboratory 
diet (LE) (2.38 kcal/g), (Koffolk, Tel-Aviv, Israel) (Table 1), 
and 2) experimental group consisting of 24 animals fed with 
commercial HE diet (2.93 kcal/g) (Table 1). In the HE group 
all the animals gained weight and developed diabetes. The 
experimental group was further divided into 2 experimental 
periods 8 and 16 weeks. Blood glucose levels and urine 
collections were monitored weekly for a period of 16 weeks. 
At the end of the experimental period, blood was drawn 
from the aorta under ketamine/xylazine anaesthesia, for the 
Table 1. Composition of the low energy (LE) and high energy (HE) diets
Diets LE HE
Protein (%) 16.2 23.6
Fat (%)    3.1   2.4
Carbohydrate (%) 70 68
NaCl (%)   1.1   1.1
Ash (%)   9.6   5.0
Digestible energy (kcal/g)     2.38     2.93Anat Cell Biol 2011;44:176-185 Pnina Scherzer, et al 178
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determinations of creatinine, glucose and insulin levels. The 
animals were killed, the abdominal cavity was opened and 
the kidneys were cut into small fragments for morphological 
evaluation.
Metabolic studies
Renal function: Renal functions were performed by mea-
suring creatinine clearance, using the endogenous creatinine 
production.
Creatinine clearance: Plasma creatinine was determined 
in blood samples obtained upon termination of the 
experiments. Urinary creatinine was determined in 4 hr urine 
collections in metabolic cages at weekly intervals. Creatinine 
levels in plasma and urine were measured using automated 
picric acid methods (Cobas Mira Analyzer, Hoffman-La 
Roche & Co., Basel, Switzerland). Creatinine clearance was 
calculated using the standard clearance formula.
Protein excretion: Urine was collected for 4 hr in me  ta-
bolic cages at weekly intervals. Urinary protein excretion was 
detected by a Pyrogallol Red direct colorimetric method in 
urine (Cobas-Mira analyzer).
Plasma glucose: Plasma glucose levels were measured 
using Glucometer Elite (Bayer Corporation, Elkhart, IN, 
USA).
Plasma insulin: Plasma insulin levels were measured 
by radioimmunoassay utilizing antibodies against human 
insulin (Medgenix, Brussels, Belgium) and human insulin as 
standard.
Histology
Kidneys were removed at 8 and 16 weeks of the experiment 
for evaluation of the histopathological changes by light and 
electron microscopy.
Light microscopy: Kidneys fragments were fixed by 
immersion for 24 hr in 4% paraformaldehyde and em  bedded 
in paraffin. Histopathology was carried out on sec  tions 
stained with hematoxyline and eosin (H&E), periodic acid 
Schiff (PAS) and Masson trichrome.
Electron microscopy: Samples of renal cortex were fixed 
by immersion in 1% glutaraldehyde in 0.1 mol/L phosphate 
buffer (pH 7.4) and processed for embedding in Lowicryl 
K4M at -20
oC as previously described [18, 19]. Tissue sections 
were mounted on nickel grids stained with uranyl acetate and 
lead citrate and examined at the electron microscope (Philips 
410LS, Phillips Ltd., Montreal, QC, Canada).
Immunocytochemistry: Other tissue sections were pro-
cessed for immunogold using an anti-mouse serum albumin 
antibody (Sigma, Oakville, ON, Canada) at 1 : 50 dilution for 
overnight at 40
oC. The sections were then rinsed with 0.01 M 
phosphate buffer saline (PBS) and incubated with the protein 
A-gold (10 nm) complex for 30 minutes at room temperature. 
The protein A-gold was prepared with 10 nm gold particles 
according to techniques described previously [18]. Upon 
thorough rinsing with PBS and wa  ter and counterstaining, 
the sections were examined by elec  tron microscopy. The 
distribution of the immunogold labeling, revealing circulating 
albumin was assessed through morphometrical evaluations as 
reported previously [18, 19]. 
Determination of glomerular size by image analysis: The 
glomerular size was measured using the segmentation tool 
of Image-Pro Plus 4.5 (Media Cybernetic, Silverspring, MD, 
USA). Digital images were taken from 40 randomly selected 
glomeruli in H&E-stained sections derived from each animal. 
All images were taken using a 63× objective and computer 
assisted-image analysis was used to measure the area of the 
glomerulus.
The circumference of each glomerulus was outlined using the 
polygonal tracing tool of Image-Pro Plus (Media Cybernetics, 
Inc., Bethesda, MD, USA). Glomerular area was computed 
utilizing the spatial measurement tool calibrated to a stage 
micrometer.
Statistical evaluation 
Results of the different groups were compared by non-
paired Student’s t-test with modified levels of significance 
according to the Godfrey method [20].
Results
Metabolic data
Animals’ body weight: Body weights of the diabetic and 
non-diabetic Psammomys at time 0, 8 and 16 weeks are 
presented in Table 2. The diabetic Psammomys, fed on HE 
diet, increased in weight by 20% during the experimental 
period, compared with the LE diet animals who served as a 
control, non diabetic group. 
Plasma glucose levels: Table 2 shows at 8 and 16 weeks 
that HE-fed Psammomys have high blood glucose levels 
during the experimental period compared to the LE-fed 
group (P<0.001). 
Blood insulin levels: During feeding with the HE diet, Psammomys: a model for diabetes nephropathy
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the Psammomys that developed diabetes showed increases in 
insulin levels up to 304±7.5 µU/ml after 8 weeks (P<0.001). 
This increase reached 550±14 µU/ml after 16 weeks, while 
it remained at low levels in the control group, 35±10 µU/ml 
(P<0.001) (Table 2). 
GFR: Fig. 1 shows the changes in the GFR of the Psam-
mo  mys during 16 weeks of the HE diet. There were no 
changes in the GFR of the control group, while in the diabetic 
Psammomys the GFR rose and doubled within 8 weeks (range, 
0.74±0.19 to 1.45±0.12 ml/min, P<0.005). The diabetic 
animals showed a decreased GFR towards normal values at 12 
weeks (0.78±0.01) and continued to drop reaching the lowest 
levels (lower than the baseline) at the end of the study at 16 
weeks (0.47±0.05). 
Protein excretion: Total protein excretion is depicted in 
Table 2. There was a gradual increase in protein excretion 
of the hyperglycemic Psammomys. Sixteen weeks after the 
HE diet was started the Psammomys developed massive 
proteinuria, about 6 times higher than that in the control 
group (P<0.001). The normoglycemic animals, fed on the LE 
diet, showed a slight increase in protein excretion during the 
experimental period (P<0.01). 
Protein/creatinine ratio: The urine protein/creatinine 
ratio of the experimental groups is shown in Table 2. In the 
diabetic animals this ratio progressively increased up to 176%, 
while in the control Psammomys the increase was only by 
47% from baseline.
Light microscopy
Glomeruli: Light microscopy revealed an increase in glo-
meruli size in the diabetes Psammomys (Fig. 2) compared 
to control animals. There was a 2.4-fold increase in the 
glomerular area of the diabetic Psammomys (P<0.001) 
(Table 3). No difference in the fibrosis was detected using the 
Masson Trichrome staining (data not shown).
Fig. 3 shows the particular appearance of special cells, the 
C-cells that are stained neither by PAS nor by H&E.
Electron microscopy
Electron microscopy (Fig. 4) revealed that these C-cells 
not stained by H&E or by PAS, are in fact tubular epithelial 
cells containing large amounts of glycogen (Fig. 4B). These 
glycogen loaded cells are tubular epithelial cells of the TAL 
and distal tubules. Their clear appearance is due to the extrac-
tion of the glycogen deposits during tissue preparation. The 
cells appeared clear with a thin rim of cytoplasm containing 
mitochondria and other cellular organelles. Microvilli and 
Table 2. Body weight, blood glucose and insulin levels, urine protein excretion and urine protein/urine creatinine ratio in the control and diabetic Psammomys at the 
beginning of the experiment (time 0) and at 8 and 16 wk of the experimental period
Time 0 8 wk 16 wk
Control Diabetes Control Diabetes Control Diabetes
Weight (g) 187.2±4.8 (n=12) 193.9±5.9 (n=24) 204.8±7.4 (n=12)     238.1±7.3* (n=24)  199.2±5.4 (n=6) 242.3±10
† (n=12)
Blood glucose (mg%)   84.1±5.1 (n=12)   73.6±3.1 (n=24)   82.7±2.2 (n=12)     306.2±43.2
†§ (n=24)    78.8±5.9 (n=6) 293.4±20.5
†§ (n=12)
Blood insulin (µU/ml) 45.3±15 (n=12) 48.5±10 (n=24)   50.5±8.2 (n=12)    304
†‡§±7.5 (n=24)     35 ±10 (n=6)  550
†§±14 (n=12)
Urine protein (mg Prot/L)    0.37±0.06 (n=12) 0.58±0.1 (n=24)  0.86
‡§±0.08 (n=12)   2.27
†‡§±0.26 (n=12)     1.28
§±0.07 (n=6) 3.53
†§±0.39 (n=12)
U-Protein/U-Creatinine (mg/μMole)    2.31±0.27 (n=12)  2.43±0.16 (n=24)  2.56±0.2 (n=12)    5.94
†§±0.51 (n=24)     3.41
§±0.33 (n=6) 6.72
†§±0.63 (n=12)
*P<0.005 vs. control, 
†P<0.001 vs. control, 
‡P<0.001 vs. time 16 wk, 
§P<0.005 vs. time 0.
Fig. 1. Glomerular filtration rate (GFR) of the control low energy (LE) 
diet and the diabetic high energy (HE) diet Psammomys after 4, 8, 12, 
and 16 weeks. Data are presented as means±SE. P<0.005 vs. controls 
animals.
Table 3. Glomerular areas (µm
2) in control and diabetic Psamommys
Time 0 8 wk 16 wk
9,340±450 (n=40) 13,358±880*
‡ (n=40) 22,635±985
† (n=40)
*P<0.005 vs. control, 
†P<0.001 vs. control, 
‡P<0.001 vs. 16 wk. Anat Cell Biol 2011;44:176-185 Pnina Scherzer, et al 180
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Fig. 2. Histology of representative glomeruli from the diabetic (high energy diet) Psammomys at the beginning of the diet (time 0) and at 8 and 16 
wk. Glomeruli area gradually increased in 8 and 16 weeks compared to time 0 (×300). Quantitative data appear in Table 3.
Fig. 3.  (A, B) PAS staining of sections of kidneys from control (low energy [LE] diet) and the diabetic (high energy [HE] diet) Psammomys after 
16 wk of feeding with the appropriate diet (×200). C, clear cells.
Fig. 4. Renal distal tubules. Epithelial cells of the control (low energy [LE] diet) (A) and a diabetic (high energy [HE] diet) (B) animals. In (A) 
the cytoplasm (cyt) appears normal with its different components, while in (B), the clear cell is filled by glycogen (gly) which was extracted during 
tissue preparation (×15,000). The cell cytoplasm appears clear; m, mitochondria; mv, microvilli; N, nucleus.Psammomys: a model for diabetes nephropathy
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basal infoldings tended to disappear. The nucleus remained 
more centrally located. These changes were not seen in the 
non-diabetic animals (Fig. 4A). 
The glomerular tuft in normoglycemic animals displayed 
the usual structures with a thin basement membrane between 
the fenestrated endothelial cells and the podocytes (Fig. 5A). 
The hyperglycaemic animals preserved the general normal 
structure of the glomerular tuft (Fig. 5B). The basement 
mem  brane, however, showed sites of enlargements as well as 
splitting into two layers (Fig. 5B). Despite these focal diffe-
rences the average thickness of the basement membrane in the 
hyperglycaemic animals was not statistically different from 
that of normoglycemic animals (164.75±9.90 nm for the HE 
diet vs. 159.25±9.10 nm for the LE diet animals). Podocytes 
also displayed normal structures with no significant fusion of 
the foot processes.
Immunocytochemistry
We applied the immunogold approach for the detection 
of circulating serum albumin. The gold particles revealed 
albumin over the capillary lumina, in association with the 
endothelial cells and in the glomerular basement membrane 
(Fig. 6). In the normoglycemic animals no labeling was 
detected in the urinary space (Fig. 6A). In the hyperglycaemic 
animals the labeling over the basement membrane appeared 
to be distributed throughout the thickness of the basement 
membrane (Fig. 6B). The gold particles were associated with 
the membranes of the endothelial cells as well as those of 
the podocytes. Some labeling was also detected over dense 
material present in the urinary space (Fig. 6B). These results 
indicate that in the diabetic animals, circulating albumin, 
besides being present in the capillary lumen, is also present 
throughout the glomerular basement membrane and in the 
urinary space. 
Morphometrical evaluation of the distribution of labeling 
through the glomerular basement membrane showed that 
in tissues of normoglycemic animals this distribution was 
asymmetrical with most of the gold particles located to-
wards the endothelial side of the basement membrane 
(Fig. 6C). Such a distribution reflects retention of albumin 
by the endothelial side of the basement membrane. In the 
hyperglycaemic animals, on the other hand, the distribution 
appears to be more uniform, with densities of labeling being 
almost as high on the podocyte side as on the endothelial side 
(Fig. 6C). These results confirm the qualitative observations 
and demonstrate that in hyperglycaemic condition, serum 
albumin crosses the glomerular wall to reach the urinary 
space.
Discussion
The present study is the first to provide a detailed des-
crip  tion of long-term renal structural changes and their 
correlation with the functional disturbances in a particular 
animal model with diabetic renal injuries. We have shown 
that the changes in renal functions and structures that 
occur in human diabetes are also present in the diabetic 
Psam  momys: there is a decrease in the GFR with a gradual 
increase in protein excretion and presence of glycogen ne-
Fig. 5. Electron micrographs of the glomerular wall of a control (low energy diet) (A) and of a diabetic (high energy diet) (B) animals.  For the 
control animal (A) the glomerular wall appears normal with a thin glomerular basement membrane (GBM) between the endothelial cell (End) and 
the podocyte (P). On the other hand, for the diabetic animal (B), the GBM, shows sites of  increase thickness and material deposition (*) as well as 
sites where the GBM splits in  two (long arrows) (×30,000). Small arrows, slit diaphragm. CL, capillary lumen; US, urinary space.Anat Cell Biol 2011;44:176-185 Pnina Scherzer, et al 182
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ph  rosis. The physiological changes at the beginning of the 
diabetic condition consisted in a doubling of the GFR, fol-
lowed by a gradual decline in GFR with the increase in urine 
protein excretion. The above pathopysiological changes were 
accompanied by glomeruli hypertrophy with leakage of 
albumin from the glomerular wall to the urinary space and 
glycogen nephrosis at the TAL and distal tubules.
Human diabetic nephropathy is characterized by changes 
in GFR with increasing proteinuria which leads to renal failure 
[2, 3]. In contrast to streptozotocin animal models used by us 
[8] as well as other models [5, 21-23] in which renal failure 
is difficult to achieve even after a 40 week follow-up, the 
diabetic Psammomys showed significant reductions in renal 
function already at 8 weeks. Increases in glomerular filtration 
rate are the earliest factional abnormality of the Psammomys 
diabetic kidney. Glomerular hyperfiltration in the early phase 
of diabetes has been widely documented in other animal 
models of diabetes and in humans [24, 25]. Others [26, 27] as 
well as our group [28-30] have hypothesized that glomerular 
hyperfiltration observed in rats with streptozotocin-in-
duced diabetes mellitus is the consequence of resting tubu-
loglomerular feedback [26-30].
As in humans, the diabetic Psammomys showed the 
same stages of proteinuria; during the experimental period 
the diabetic animals developed microalbuminuria that 
progressively reached the degree of massive proteinuria. The 
increment in protein excretion was followed by impaired 
glomerular filtration rates (Fig. 1). 
In different rat models of type 2 diabetes, proteinuria was 
also observed. However, those investigations were not able to 
correlate the proteinuria with the changes in GFR [22, 23, 31, 
32]. This lack of correlation displayed by different models of 
diabetes in rats and mice, as opposed to the one present in the 
diabetic Psammomys, emphasizes the closeness of this model 
Fig. 6. (A, B) Immunocytochemical detection of endogenous serum albumin by the protein A- gold technique. Glomerular walls of a control (A) 
and a diabetic animal (B). The gold particles reveal that serum albumin antigenic sites are present in large amounts over the capillary lumen (CL) 
and over the glomerular basement membrane (GBM). In the control animals (A), the labeling appears to be mainly on the endothelial side of the 
basement membrane, and no gold particles are seen in the urinary space (US). Arrow: slit diaphragm. For the diabetic animal (B), the labeling 
over the GBM appears to be distributed throughout the GBM and we can detect dense labeled areas in the urinary space (arrowheads) (×40,000). 
P, podocyte; End, endothelial cell. (C) Distribution of serum albumin immunolabeling across the glomerular wall as expressed over ratio values 
(R). In the control animals the distribution is asymmetrical, demonstrating that most of the albumin is retained on the endothelial side of the 
glomerular basement membrane. The distribution for the diabetic animals is more uniform across the basement membrane indicating alteration in 
the passage of albumin across the glomerular wall.Psammomys: a model for diabetes nephropathy
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with the human nephropathy and its potential as a better tool 
for the investigation and understanding diabetes. 
The initially basic proteinuria of our control animals 
slightly increased during the experimental period, confirming 
that proteinuria is normally present in rodents [33, 34], and 
the slight increase may be due to aging.
Anatomical-functional correlation
The important results of this communication are the histo-
logical changes observed in the glomeruli and tubules of the 
Psammomys diabetic kidney.
The histological changes of the glomeruli: In the glo-
meruli we found progressive hypertrophy, with leakage of 
albumin from the glomerular capillary into the urinary space. 
Renal hypertrophy is common in diabetes, in humans as 
well as in animal models. Although is not well understood 
this finding has been generally attributed to glomerular 
hyperfiltration. Our present study raises certain questions 
regarding the correlation between glomerular hyperfiltration 
and glo  merular hypertrophy in the diabetic Psammomys. 
In the very early phase of diabetes in the Psammomys, glo-
merular hyperfitration is associated with glomerular hyper-
trophy. Inter  estingly, as the hyperglycemic state continues, the 
glo  merular filtration returns to normal levels at 12 weeks, and 
then falls far below those of control levels at 16 weeks. Despite 
this significant drop in glomerular filtration rate (two-fold 
below control) there is a dramatic increase in glomerular 
volume. This paradoxical inverse morphological - functional 
correlation in the present study is not yet understood. 
The marked drop in the glomerular filtration rate at 16 
weeks is most likely due to alteration in the filtering bar-
rier of the glomerular tuft, which consists of endothelial 
cells, basement membrane and visceral epithelial cells (the 
podocytes). In fact, experimental studies by Myers et al. [35] 
have shown a decrease in glomerular filtration coefficient (Kf) 
in this setting. These investigators have demonstrated in the 
diabetic kidney a reduction in the number of restrictive pores 
that leads to loss of ultrafiltration capacity. Parallel to the fall 
in filtration capacity, there is an impairment of glomerular 
barrier size selectivity leading to progressive albuminuria [36, 
37].
Histopathological changes of the tubule: The present 
study has shown that the earliest morphological change noti-
ce  able by light microscopy (Fig. 3) in the diabetic Psammomys 
kidney is the appearance of glycogen deposits in the tubular 
epithelial cells of the distal nephron (Fig. 4). Similar findings 
were reported in rat kidney with streptozotocin-induced dia-
betes mellitus [38]. This pathological abnormality is known 
in diabetic patients as glycogen nephrosis or Armanni-
Ebstein. With insulin therapy in humans, the incidence and 
severity of the lesion became less pronounced [39]. The 
pathophysiological importance of glycogen accumulation 
in epithelial cells is not yet fully understood. Theoretically, if 
localized to the macula densa glycogen-induced injury could 
potentially interfere with the tubuloglomerular feedback. 
Consequent inhibition of vasoconstrictor signalling to affe-
rent arteriole would contribute to afferent arteriolar dilatation 
leading to an increased glomerular capillary hydraulic 
pressure and hyperfiltration. Meyer et al. [40], by investigating 
the renal and hepatic glucose metabolism in type 2 diabetes 
in humans, indicated that renal glucose uptake is markedly 
increased in type 2 diabetes; which could explain the accumu-
lation of glycogen found in diabetic kidneys where it triggers 
cell apoptosis leading to renal failure.
Increased renal deposits of glycogen in diabetic humans 
and rats have been the object of extensive investigations 
[16, 41, 42]. Various studies agree that the predominant 
location of the pathologic glycogen accumulation is in the 
TAL, whereas less extensive deposition occurs in the distal 
tubules and in other portions of the nephron [16, 38, 41, 43-
45]. Whether glycogen accu  mu  lation interferes with the 
physiological functions of the affected segments is uncertain. 
Normally, in physiological states, a major function of the 
TAL is sodium chloride reab  sorp  tion. The highest activity 
of the Na-K-ATPase activity is in the medulla of the kidney 
and especially in the TAL because of its role in controlling 
the hyperosmolarity of the medulla. Structurally, the Na-K-
ATPase is localized in the cell membrane of the large and 
numerous basal infoldings. In our previous report on diabetic 
Psammomys [14] we clearly demonstrated that Na-K-ATPase 
activity was determined by glomerular filtration. We also 
showed a decrease in Na-K-ATPase activity in the medulla of 
the Psammomys with GFR values below those in the control 
group. Here we show that in long-term diabetes there are 
glycogen-containing cells located in the TAL, with reduced 
basolateral infoldings.
Taking together these findings we can propose that the 
decrease in renal function of the diabetic Psammomys may 
be caused by the structural changes that happened in the 
glycogen containing cells in the TAL that led to reduced 
activity of the Na-K-ATPase enzyme. It is possible that this 
reduction in enzyme activity in the medulla of the dia-Anat Cell Biol 2011;44:176-185 Pnina Scherzer, et al 184
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betic Psammomys [14] is part of the progression of renal 
disease. Tubular apoptosis found associated with glycogen 
accumulation [41] must contribute significantly to the 
diabetic nephropathy. Support for this possibility is provided 
by the finding that patients with type I glycogen storage 
disease frequently develop renal disease [46]. Moreover, 
striking similarities between diabetes mellitus and inherited 
glycogen storage disease with regard to renal pathology 
have been well documented [46]. Glycogen deposits in the 
kidney are the first shared morphological features early in 
both diseases [47]. Interestingly, the pathophysiology in 
both conditions is almost identical [46-48]. Furthermore, 
the analogy encompasses the natural history of both diseases 
that follow an inexorable detrimental course of progression 
to glomerular sclerosis with proteinuria and hypertension, 
culminating in end-stage renal disease [46-48].
In summary, the results of the present study demonstrate 
parallel physiological and histological changes in the diabetic 
Psammomys kidney and human diabetes. We have shown: 
1) close relationships between structural changes such as 
increasing glomerular size with leakage of albumin from 
the glomerular wall to the urinary space; 2) the existence of 
glycogen-containing cells with the physiological changes, e.g. 
reduction of the GFR and massive proteinuria. Accordingly, 
the diabetic the Psammomys appears to be an excellent model 
for the study of the human diabetic renal failure.
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